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ABSTRACT
Santa Catarina is a Brazilian State that has reported the lowest prevalence of human 
T-cell lymphotropic viruses (HTLV-1/2) in blood donors (0.04%). Although it presents ports, 
airports and roads that facilitate the entrance and dissemination of new infectious agents, no 
information exists concerning the HTLV-1/2 infections in HIV/AIDS patients. This study 
searched for HTLV-1/2 antibodies in plasma samples of 625 HIV/AIDS patients from the 
municipality of Tubarao (Southern Santa Catarina), and disclosed 1.1% of positivity (0.48% 
HTLV-1, 0.48% HTLV-2 and 0.16% untypeable HTLV), and a positive correlation with the 
male sex (OR 4.16) and intravenous drug use (OR 35.18). Although the percentage of 1.1% 
appears to be low, it is 27.5 times higher than the percentage detected in blood donors. Since 
HTLV-1 and HTLV-2 are circulating in HIV-infected individuals in Southern Santa Catarina, 
and these retroviruses could cause a differently impact on the HIV/AIDS outcomes, the 
surveillance of HTLV-1/2 is necessary, and it could support public health policies in preventing 
the transmission and dissemination of these viruses in this State. 
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INTRODUCTION
The first retrovirus identified in human beings, named human T-cell lymphotropic 
virus type 1 (HTLV-1), has been the etiological agent of at least two important 
diseases of high lethality and morbidity: the adult T-cell leukemia/lymphoma (ATLL) 
and the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)1,2. 
The second human retrovirus, named HTLV-2, although originally isolated from a 
patient with hairy T-cell leukemia, was later not confirmed to be associated with the 
specific disease, making its pathogenicity questionable1. Nonetheless, when these 
human retroviruses are associated with HIV, they are claimed to affect the HIV 
patient’s progression towards AIDS. HTLV-1 has been associated with the rapid 
progression and death due to AIDS3,4, whereas the HTLV-2 has been associated with 
slow progression towards AIDS5. Thus, the search for HTLV-1/2 in HIV-infected 
individuals has a prognostic value. 
Brazil, a country of more than 200 million inhabitants, is an important 
endemic area for HTLV-1 infection and associated diseases in the world, 
estimated to 800,000 HTLV-1-infected people2. HTLV-2 is endemic among the 
indigenous populations of the Brazilian Amazon region and among intravenous 
drug users (IDU) in urban areas, co-infected or not with HIV6. The Brazilian 
Ministry of Health recommends HTLV-1/2 serological testing at the beginning 
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of HIV-1-infected patients’ follow-up, mostly in regions 
where the HTLV-1 is endemic7.
Despite having a heterogeneous geographic distribution 
in Brazil, HTLV-1/2 discloses the lowest prevalence rate 
in blood donors (0.4/1.000 blood donors or 0.04%) in the 
Santa Catarina State8,9, which has 47,461 cases of AIDS. 
The data collected during the period from 2000 to 2017 
showed an AIDS notification rate of 26.8 cases per 100,000 
inhabitants, which is higher than the national rate (18.3 
per 100,000 inhabitants), described during this period10,11.
There are no data available regarding HTLV-1 and 
HTLV-2 in HIV-1-infected individuals from Santa Catarina 
State. Considering that the airports, ports and roads of 
this State facilitate the entrance and dissemination of new 
infectious agents, as occurred with the HIV-1 subtype C 
in Brazil12, a survey on HTLV-1/2 infection is necessary 
and relevant. 
MATERIALS AND METHODS
A cross-sectional study on HTLV-1/2 serology was 
conducted by analyzing plasma samples from 625 HIV/AIDS 
patients with a mean age of 43 years (range 18-84 years, 
59.4% men) attending a specialized HIV/AIDS diagnosis 
and treatment center in the municipality of Tubarao 
(Centro de Atendimento Especializado em Saude - CAES). 
The CAES has registered 1,417 patients, including 
those with tuberculosis and hanseniasis, encompassing 
18 municipalities of Southern Santa Catarina: Armazem, 
Braco do Norte, Capivari de Baixo, Grao Para, Gravatal, 
Imarui, Imbituba, Jaguaruna, Laguna, Pedras Grandes, 
Pescaria Brava, Rio Fortuna, Sangao, Santa Rosa de Lima, 
Sao Ludgero, Sao Martinho, Treze de Maio and Tubarao. 
Blood samples were collected from the patients from 
October 2016 to July 2017 to determine CD4 and CD8 cell 
counts and HIV viral load quantification, and only plasma 
samples were stored in a repository for further analysis. The 
socio-demographic data and the potential risk factors for 
HIV infection were obtained from a standardized individual 
questionnaire, which was applied by a trained interviewer. 
Data concerning the number of CD4 cell counts, HIV viral 
load quantification, highly active antiretroviral therapy 
(HAART) usage, and clinical manifestations were obtained 
from medical records. The stored plasma samples were 
sent to the Instituto Adolfo Lutz (IAL), a Public Health 
Laboratory in Sao Paulo, for the detection of HTLV-1/2 
antibodies. These samples were analyzed after obtaining 
the informed consent from patients, and the protocol 
approval from the Ethic Committees of both institutions 
[IAL, CAAE Nº 96885118.6.3001.0059, and Universidade 
do Sul de Santa Catarina (UNISUL) and CAES, CAAE 
Nº 96885118.6.0000.5369]. All procedures were performed 
in accordance with the Resolution 466/2012 of the Brazilian 
National Health Council (CNS) on Ethics in Research with 
Human Beings.
The plasma samples were screened for HTLV-1/2 
antibodies at the HTLV Research Laboratory of the 
Immunology Department of IAL by using an enzyme 
linked-immunosorbent assay Gold ELISA HTLV-1/2 
(REM Industria e Comercio LTDA, Sao Paulo, Brazil), 
and confirmed by Western Blot (WB) (HTLV BLOT 2.4, 
MP Biomedicals, Asia Pacific Pte Ltd, Singapore) and line 
Immunoassay (INNO-LIA HTLV I/II, Fujirebio, Europe 
N.V, Belgium). Reactions were performed and interpreted 
according to the manufacturer’s instructions. Noteworthy, 
HTLV-1/2 molecular confirmatory assay was not performed 
because of the lack of cells for analysis.
RESULTS
The screening assay detected eight reactive samples. 
HTLV-1/2 infection was confirmed in seven samples (1.1%): 
HTLV-1 (0.48%), HTLV-2 (0.48%), and HTLV positive 
but untypeable (0.16%). An association between male 
individuals and IDUs was observed (Table 1). In relation to 
the age, although the coinfected patients had a mean age of 
49.7 years old, their HIV-mono-infected counterparts had a 
mean age of 42.9, but no statistic difference was observed. 
However, six out of seven HIV/HTLV-coinfected patients 
were aged 48 to 60 years old; and only one was 29 years 
old. The distribution of patients according to the age group 
is in Figure 1, emphasizing that the majority of HIV/HTLV-
coinfected patients were aged 51 to 60 years old.
Of note, among HIV/AIDS patients 88.1% were on 
HAART and 74.1% had undetectable HIV viral load. 
Among HIV/HTLV-coinfected patients, all except one 
were on HAART and had undetectable HIV viral load. 
The naïve patient was a man of 52 years old, IDU, HIV/
HCV/HTLV-1-coinfected, with a CD4 count of 273 cells/
mm3 and HIV viral load of 77,491 copies/mL, and he died 
of pneumonia. Another coinfected patient who died during 
follow-up was the 29 years old man. Curiously he was HIV/
HTLV-2-coinfected, denied IDU, had a CD4 count of 635 
cells/mm3 and undetectable HIV viral load; had a history of 
syphilis, tuberculosis and pneumocystosis, and died after a 
non characterized heart attack. The other coinfected patients 
remain alive, on HAART, and with HIV undetectable viral 
load. None HIV/HTLV-coinfected patient presented any 
HTLV-associated neurological diseases.
Comparative analysis of CD4 cell counts among HIV/
AIDS mono-infected patients (mean of 507.5 cells/mm3) 
and coinfected patients (mean of 403.0 cells/mm3 in HIV/
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HTLV-1, 475.0 cells/mm3 in HIV/HTLV-2, and 145.0 cells/
mm3 in HIV/HTLV co-infected patient) were not feasible 
because of the low number of HIV/HTLV-1/-2-coinfected 
individuals. Thus, neither clinical nor statistical correlations 
were performed. 
DISCUSSION
Although the percentage of 1.1% of HTLV-1/2 
seropositivity appears to be low, it is 27.5 times higher than 
the positivity detected in blood donors in Santa Catarina 
State8,9, and this is of concern. In addition, both HTLV-1 and 
HTLV-2 circulate in this region, and this is somewhat similar 
to that observed in Sao Paulo State where both, HTLV-1 and 
HTLV-2 were detected in HIV/AIDS patients13-15. In fact, this 
could be due in part to the mixed population living in Sao 
Paulo, which is composed of immigrants and migrants from 
elsewhere in the country and in the same way, this is the same 
situation found in Southern Santa Catarina. This region has 
an airport, two ports (Imbituba and Laguna), and the federal 
freeway BR101 beside others, allowing the contact with 
foreign people within Brazil, coming from Latin American 
countries and abroad (Figure 2). In addition, the transmission 
route and the age of HIV/HTLV-coinfected patients from 
Table 1 - Demographic characteristics (number, age, sex and risk factors) of overall HIV-infected and HIV/HTLV-1/2-coinfected 







HTLV-1 (n=3) HTLV-2 (n=3) HTLV (n=1)
Age in years1      
Female 42.7 60.0 - -  
Male 43.0 50.0 43.0 59.0  
Sex2   
Female 253 (40.9) 1 (14.3) - -  
Male 365 (59.1) 2 (28.6) 3 (42.8) 1 (14.3) 4.16 (0.50 - 92.22)
Exposure to HIV2      
Sexual 433 (70.0) 1 (14.3) 1 (14.3) -  
IDU 41 (6.6) 2 (28.6) 2 (28.6) 1 (14.3) 35.18 (5.80 - 271.11)
Mother-to-child 11 (1.8) - - -  
Blood transfusion 5 (0.8) - - -  
Accident with blood 15 (2.4) - - -  
Unknown 113 (18.3) - - -  
1Median; 2Number (%); n: number of individuals; IDU: intravenous drug user; OR: odds ratio; CI: confidence interval of 95%.
Figure 1 - Percentages of overall HIV-infected and HIV/HTLV-1/2-coinfected patients from Southern Santa Catarina, Brazil, 
according to the age group.
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Sao Paulo and Southern Santa Catarina are quite similar. In 
both States, there was a strong association with IDU (OR 
30.01 and OR 35.18, respectively), and the mean age of 50 
years old was observed13. Interestingly, the only patient of 
29 years old acquired HIV and probably HTLV-2 by sexual 
route, and although on HAART, presenting undetectable viral 
load and a good CD4 cells count, he died as a consequence 
of a fulminant heart attack, probably due to lipodystrophy. 
Worthy of note, only one study concerning HTLV-1/2 
in at-risk individuals from Santa Catarina is available. 
It was conducted by our group, analyzing 90 female sex 
workers from the same geographical region of this study. 
One HTLV-1-positive pregnant woman was detected, and 
she was advised not to breastfeed her offspring16. 
Other studies from Southern Brazil were carried out 
in the municipality of Londrina, Parana State, Brazil. 
High percentages of HIV/HTLV-coinfections in 758 HIV/
AIDS patients (5.7%) were found, and there was also 
association with IDU (OR 10.72) and HCV (OR 30.36). A 
high prevalence of HTLV-2 as compared to HTLV-1 (4.9% 
versus 0.8%, respectively) was detected17,18. 
One study conducted in Porto Alegre, Rio Grande do 
Sul State, Brazil showed the occurrence of 2.4% of HIV/
HTLV coinfection (1.4% HTLV-1, 0.5% HTLV-2, and 
0.5% untypeable HTLV) in 2,985 patients, seen at three 
HIV counseling centers in Porto Alegre, associated with 
intravenous cocaine use (p< 0.001) and HIV positivity 
(p<0.001)19.
Figure 2 - Maps of the Latin America, Brazil, and Santa Catarina State, with emphasis on the Laguna region, and the 18 municipalities 
from where blood samples were collected. Location of the airport, the ports [Imbituba (North) and Laguna (South)], the freeway 
BR101 and the municipality of Tubarao are depicted. 
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More recently, another study employing molecular 
assays for confirming HTLV-1/2 infections, conducted on 
580 HIV-infected individuals from the metropolitan area of 
Porto Alegre, showed 2.9% of HIV/HTLV-1/2 coinfection 
(1.9% HTLV-1 and 1.0% HTLV-2)20. All of these studies 
confirm the occurrence of HTLV-1 and HTLV-2 in Southern 
Brazil.
Noteworthy, at present the major routes of HTLV 
transmission in Brazil are the sexual and the vertical21, 
but from 1980 to 2000, the parenteral route predominated, 
mostly among IDU who became infected with HTLV-2 in 
the South and Southeast regions in Brazil, as previously 
described13,15,18,22,23. On the other hand, in the Northeast 
Brazil, HTLV-1 predominated among IDU24, and these 
findings could be related to the differences in HTLV-1 and 
HTLV-2 endemic areas, as well to the different patterns 
of drug usage. In fact, studies from 2000, described the 
Brazilian Harm Reduction Programs that provided sterile 
syringes and needles to IDU, and the change in drug use from 
intravenous cocaine to crack cocaine. They emphasize the 
drastic reduction in the number of HIV, and probably HTLV 
infected individuals in Brazil13,25,26. Herein, the older age of 
HIV/HTLV-coinfected patients, and the strong association 
with the male sex and IDU corroborate these data. 
Taken together, the results detected in this first survey 
on HTLV-1/2 in HIV/AIDS patients from Southern Santa 
Catarina revealed the occurrence of HTLV-1 and HTLV-2 
circulating among HIV-infected individuals. Given that 
these retroviruses could cause different impacts on HIV/
AIDS outcomes, the surveillance of HTLV-1/2 is necessary, 
and it could support public health policies in preventing 
the transmission of these retroviruses. The authors of the 
present study are currently interested in expanding these 
data, searching for sexually transmitted diseases, including 
HTLV-1/2 in other at-risk populations, such as sex workers, 
lesbians, gays, bisexual men, and transgender individuals 
from this geographical area.
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